Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
The revised classification includes many authors of the prior WHO edition but is not affiliated with the WHO.
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse.
Nicholas J. Short, MD, speaks about how novel chemotherapy can eliminate the need for transplant in ALL.
A deeper understanding of ALL has led to more targeted approaches and personalized treatments for this patient population.
A UK regulator granted an Innovation Passport to ALETA-001 for patients with non-Hodgkin lymphoma and ALL.
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
CRISPR/Cas9 technology was used to engineer donor T cells to treat children with pediatric B-ALL.
Frontline sequential chemotherapy with blinatumomab resulted in encouraging long-term survival in B-cell ALL.
Blood Cancers Today Associate Editor Elias Jabbour, MD, gave his thoughts on the first day of the 2022 SOHO Annual Meeting.
The 2022 SOHO Annual Meeting kicked off with remarks from 2022-2023 President Moshe Talpaz, MD.
September is Blood Cancer Awareness Month.
Aaron Logan, MD, PhD, and Elias Jabbour, MD, discussed whether MRD negativity indicates a cure in patients with AML.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has issued...
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
Advances have been accomplished in the management of adults with acute lymphoblastic leukemia...
Transplant was associated with a lower incidence of disease relapse but did increase the mortality related to treatment.
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation and Rare Pediatric...
The FDA has granted Fast Track Designation and Rare Pediatric Disease Designation for WU-CART-007.
A new study found that more than one-third of patients aged older than 65 years do not receive...
Treatment produced an overall response rate of 87.5% in those with BM disease and a 85.4% remission rate in those with CNSL.
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Assistant Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Advertisement
670 Madison Ave.
Manalapan, NJ 07726
© 2022 Mashup Media, LLC. All rights reserved.